Target: IFN beta.
Clone: MIB-5E9.1.
Specificity: Anti-IFN beta In Vivo Antibody - Low Endotoxin (MIB-5E9.1) recognizes Mouse IFN beta.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: Fibroblasts & epithelial cells.
Background: Interferons (IFN) consist of two classes. The type I IFN class consists of 20 highly similar IFN-alpha proteins and a single IFN-beta protein. The second class, type II IFN, consists of a single protein, IFN-gamma. IFN-alpha and IFN-beta signal through the same cell surface receptor IFNAR1 and have a similar range of biological activities including antiviral and antiproliferative activity. The type I IFNs also influence activation, growth and differentiation of T cells, B cells, macrophages, NK cells and other cell types such as endothelial cells and fibroblasts. IFN-beta has recently proven to be beneficial in patients with multiple sclerosis and could also be a potential therapy for rheumatoid arthritis. It is unclear what cellular mechanisms are involved in IFN-beta’s therapeutic effects, but they may be caused by a restoration of balance between pro- and anti-inflammatory cytokines.
Concentration: 1.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >95% by SDS-PAGE and HPLC.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
